
').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Topics
Biocon | stock market trading

').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Integrated Core Strategies (Asia) Pte on Tuesday bought shares of biopharmaceutical company Biocon for Rs 185 crore through an open market transaction.
According to the bulk deal data available with the National Stock Exchange (NSE), Integrated Core Strategies (Asia) Pte purchased 80,61,599 shares at an average price of Rs 229.26 each share. The aggregate deal value is Rs 184.82 crore.
Details about the sellers could not be immediately ascertained.
On Tuesday, shares of Biocon closed marginally lower at Rs 229.50 apiece on NSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
First Published: Tue, February 28 2023. 22:06 IST
Revolut has spent much of its life insisting that it is more than a bank. In Australia, it has now decided that becoming... Read more
Artificial intelligence is no longer something banks discuss as a distant possibility. It is already working behind the ... Read more
ClearBank has spent much of the past decade building the technology and regulatory infrastructure needed to challenge so... Read more
ClearBank’s progress shows that modern clearing and banking infrastructure can become a sizeable and profitable busine... Read more
There is something quietly symbolic about JPMorgan Chase choosing Berlin as its gateway into continental Europe. In a fo... Read more
There is a moment in every bull run when the narrative starts to fray. Not with a crash, not with a scandal, but with so... Read more